Patient Oriented Research in Transplant and Oncology ID

描述（由申请人提供）：这是为约翰·霍普金斯大学 (JHU) 医学院的 Kieren A. Marr 医学博士申请 K24 以患者为导向的研究 (POR) 职业生涯中期奖的提案。 Marr 博士最近成为约翰霍普金斯大学传染病科移植和肿瘤传染病项目主任。该奖项支持领导这一新开发的学术移植和肿瘤学 ID 项目的宏伟目标，近期目标是建设基础设施，以便对感染并发症进行结构化教学和研究，并启动机构研究的新方向。主要目标是： 1. 为移植和肿瘤传染病的临床和转化研究制定全面的学术培训计划； 2. 通过进行前瞻性维护的动态队列研究并建立一个结合了移植和肿瘤学数据库、感染控制记录和电子病历要素的数据库，定义流行病学和感染性疾病结果的趋势。作为目标 2 的一部分，将建立新项目来确定肿瘤患者中艰难梭菌感染的流行病学和结果，并确定实体器官移植高危受者的感染并发症。这些目标将在为新任和现有初级教师、研究员和研究生提供指导的背景下得到实现。 K24 将使 Marr 博士能够更有效地追求她的长期职业目标，即在约翰霍普金斯大学开发一个“世界一流”的学术项目，专门从事移植和肿瘤患者独特的 ID 护理，并建立一个专注于预防和治疗机会性感染的多学科转化临床研究项目。

DESCRIPTION (provided by applicant): This is a proposal for a K24 Mid-career award in Patient-oriented research (POR) for Kieren A. Marr MD, of the Johns Hopkins University (JHU) School of Medicine. Dr. Marr recently became the Director of the Transplant and Oncology Infectious Diseases Program in the Division of Infectious Diseases at JHU. The award supports the large goal of enabling leadership of this newly developed academic Transplant and Oncology ID program, with immediate goals of building an infrastructure to allow for structured teaching and research on infectious complications and initiating new directions of institutional research. The principal aims are to: 1. Develop a comprehensive academic training program for clinical and translational research in Transplant and Oncology Infectious Diseases; and 2. Define trends in epidemiology and ID outcomes by performing a prospectively maintained dynamic cohort study and building a database that combines elements from transplant and oncology databases, infection control records, and electronic medical records. As part of aim 2, new projects will be established to define the epidemiology and outcomes of Clostridium difficile infection in oncology patients, and to define infectious complications in high-risk recipients of solid organ transplants. These aims will be addressed in the context of providing mentorship to new and existing junior faculty, and to fellows and graduate students. The K24 will allow for Dr. Marr to more effectively pursue her long-term career goals of developing a "world-class" academic program at Johns Hopkins that specializes in the unique ID care of transplant and oncology patients, and building a multidisciplinary translational clinical research program focused on prevention and treatment of opportunistic infections.